Articles On Invion (ASX:IVX)

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

Life-sciences company Invion (ASX: IVX) has published results from a pre-clinical study that could eventuate into an important development for women’s health. Research conducted by the Hudson Institute of Medical Research in Australia indic...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Melbourne-based Invion (ASX: IVX) will collaborate with world renowned research organisation Peter MacCallum Cancer Centre (Peter Mac) regarding pre-clinical research into the impact of Invion’s photodynamic therapy on penile and anal cance...

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...

It has been a slow start to the new fiscal year, with the list of planned IPOs thinning out. There’s just seven companies on the ASX’s list of IPOs hoping to hit the boards this month and next. According to the bourse’s market stats, initia...

Biotech company Invex Therapeutics (ASX:IVX) got off to a flyer when it joined the ASX boards on Friday. The company raised $12m at IPO via the issuance of 30m shares at 40c each. The stock commenced trading at 60c and closed on Friday at $...